## **Biostatistics statement**

To whom it may concern

Title: Sorafenib plus transarterial chemoembolization versus sorafenib alone for patients with advanced hepatocellular carcinoma: A system review and meta-analysis

The letter is to confirm that I have read the ethics application prepared for this study, and that in my opinion the statistical methods and techniques mentioned are appropriate for the research.

Please contact me if you have any queries.

Sincerely,

Kai Chen

Department of Pharmacy, The Affiliated Taizhou People's Hospital of Nanjing Medical University Taizhou, China E-mail: